Response Genetics sales and marketing update

Response Genetics added both FISH- and PCR-based testing for c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements to its lung cancer panel. The company said ROS1 testing supplements its EML4-ALK real-time PCR test, which was launched in June to identify anaplastic lymphoma kinase (ALK) rearrangements in a sub-population of non-small cell lung cancer (NSCLC) patients who had negative results with the ALK Break Apart FISH test and may respond to Xalkori crizotinib. The company noted that published studies have shown that "ROS1 driven tumors are sensitive" to Xalkori. ...